ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1680

Predictivity Of Serum Biomarkers For Disease Activity In a Prospectively Followed-Up Takayasu Arteritis Cohort: Is Serum Amyloid A Protein Better Than Conventional Acute Phase Markers?

Ahmet Omma1, Burak Erer2, Nilufer Alpay3, Nuray Gurel Polat4, Ahmet Gul1, Murat Inanc4, Lale Ocal1 and Sevil Kamali1, 1Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Department of Internal Medicine, Rheumatology Division, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 3Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 4Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Takayasu arteritis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Takayasu arteritis (TA) is a chronic vasculitis with an indolent course. Reliable diagnostic and activity markers have not yet been demonstrated. We aimed to evaluate the predictivity of conventional acute phase proteins (ESR, CRP) and other non-conventional inflammation and endothelial activity markers such as serum amilod A (SAA) protein, interleukin-6 (IL-6) and von Willebrand factor (vWF) in a TA cohort, prospectively followed-up.

Methods: Fourty-eight TA patients diagnosed according to ACR 1990 criteria and followed-up ≥ 6 months, 37 patients with granulomatosis with poliangiitis (GPA) diagnosed according to ACR 1990 criteria and 28 healthy controls (HC) were included into the study. Demographic and clinical features of TA, GPA and HCs were recorded into a predefined protocol. ESR, CRP, SAA, IL-6 and vWF levels were analysed initially in all groups and at  3rd, 6th, 12th months visits in TA and GPA groups. Westergreen method for ESR, nephelometric assay for CRP, SAA and ELISA method for IL-6 and vWF were used. Disease activity was evaluated by Kerr criteria for TA and BVAS2003 for GPA. TA and GPA cohorts were stratified to the subgroups according to the activity. Comparisons were performed by Mann Whitney U test in subgroups. ROC curve analysis was used to identify the sensitivity and specificity of laboratory parameters for predicting activity.

Results: Mean age and disease duration were found as 40±13 yrs, 121±115 mo for TA, 47±13 yrs, 65±42 mo for GPA and mean age was 38±9 for HCs. Females were significantly high in TA cohort (%) when compared to GPA (%) (p<0,001). The percentage of active disease was 40%, 31%, 35%, 29% for TA and 32%, 19%, 11%, 13% for GPA at initial 3rd, 6th and 12th months, respectively. ESR, CRP and SAA levels were significantly high in active TA at the initial, 3rd, and 6th months visits (41±20 vs 21±12, p=<0.001 for ESR, 20±20 vs 6±10 p=<0.001 for CRP, 23±23 vs 12±29, p=0.001 for SAA at initial visit, 41±19 vs 24±17, p=0.002 for ESR, 26±28 vs 6±8, p= 0.004 for CRP, 38±59 vs 12±17, p=0.02 for SAA at the 3rd visit, 41±17 vs 24±12, p= <0.001 for ESR, 16±18 vs 4±5, p= 0.01 for CRP, 22±30 vs 10±16, p=0.002 for SAA at the 6th visit). SAA was the only marker that demonstrate the significance between subgroups at the 12th month (12±10 vs 8±11, p= 0.007). In active GPA subgroup, SAA and vWF at the 3rd visit and vWF at the 6th visit were found significantly high compared to inactive patients. Sensitivity and specificity were found as 88-70%, 79-84% for ESR levels of 35 mm/h, 83-65%, 86-84% for CRP levels of 5-8 mg/L 72-50%, 90-80% for SAA levels of 10-11 mg/L at the initial and 6th months visits in TA cohort. At the 12th month visit, SAA levels of 9 mg/L, was the only marker reaching the significant sensitivity (45%) and spesificity (83%) for predicting activity.

Conclusion: In a well established and prospective cohort of TA, SAA has found to be a comparable sensitivity and specificity with ESR and CRP for predicting activity. It’s been observed that sensitivity of ESR, CRP had a trend towards to decrease in time which could be related to the decreasing activity during the follow-up. SAA was the only laboratory parameter which maintained its specificity in contrast to conventional biomarkers.


Disclosure:

A. Omma,
None;

B. Erer,
None;

N. Alpay,
None;

N. Gurel Polat,
None;

A. Gul,
None;

M. Inanc,
None;

L. Ocal,
None;

S. Kamali,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictivity-of-serum-biomarkers-for-disease-activity-in-a-prospectively-followed-up-takayasu-arteritis-cohort-is-serum-amyloid-a-protein-better-than-conventional-acute-phase-markers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology